Masimo stock price target raised to $180 by Jefferies on Danaher deal

Danaher announced it will acquire Masimo for $9.9B ($180/share); Jefferies raised its Masimo price target to $180 (from $168) while keeping a Hold. The deal values Masimo at ~18x 2027 EBITDA (20x P/E) pre-synergies and ~15x EBITDA post-synergies versus Masimo's current EV/EBITDA of 28.14, implying a relative discount. Masimo posted preliminary 2025 revenue of ~$1.52B (up 9%) and Q4 revenue of ~$411M (up 12%); the stock trades at $178.43 near its $179 52-week high. Raymond James downgraded the stock to Market Perform, citing expectations the deal will close without competing bids in Q2–Q3 2026.

Analysis

The headline M&A dynamic compresses a cluster of second-order winners and losers: acquirers with deep direct-sales networks and scale-driven services (after successful integration) can monetize cross-sell and recurring consumables, while mid-tier suppliers of sensors and proprietary components face a bargaining reset as purchasing consolidates. Expect gross-margin reallocation pressure on those suppliers and potential voluntary SKU rationalization at hospital customers; that creates idiosyncratic shorts in small, single-product suppliers and long opportunities in low-cost, high-volume component producers with diversified end markets.

Regulatory, financing, and litigation vectors remain the largest asymmetrical risks. A prolonged review, a competing bid, or a surprise contingent liability disclosure would reprice the target by >30% on deal uncertainty alone; conversely, modest integration execution delays can still leave substantial realized synergies over 12-36 months. Macro credit conditions matter: tighter spreads or a reset in market valuations could widen the arbitrage spread and increase probability of renegotiation or walk-away scenarios.

From a thematic angle, the move accelerates voluntary consolidation within clinical AI and monitoring stacks — larger platforms can bundle AI risk-assessment tools with device workflows, pressuring stand-alone AI vendors to pursue either partnership or exit. That creates a near-term tactical window to trade basis between target equity, acquirer equity, and selected suppliers: the arbitrage is a function of deal certainty, not product merit, so position sizing and hedges should be calibrated to regulatory/litigation event-risk rather than multiples alone.

Key Decisions for Investors

• Event-arb pair (6–12 month horizon): Long MASI equity sized to conviction (e.g., 2–4% NAV) while shorting DHR proportionally to neutralize beta and sector exposure. Rationale: capture spread to deal-close while isolating idiosyncratic deal risk; risk: deal break -> long target falls sharply; reward: spread capture near 100% of current arbitrage. Tighten or exit on early regulatory filings or litigation headlines.
• Protective collar (6–18 month horizon): Own MASI shares but buy a floor via an out-of-the-money put spread and sell near-term calls to fund cost. Rationale: preserves upside if deal completes or re-rates, limits tail loss if transaction collapses; risk/reward: cap upside (calls) vs downside protection (puts) with well-defined max loss.
• Leverage via options (12–24 month horizon): Buy long-dated MASI calls (e.g., Jan 2027) sized small (0.5–1% NAV) to capture asymmetric upside if competing bids or better-than-expected synergy delivery appears. Rationale: limited downside (premium) but high convexity if strategic interest accelerates. Monitor gamma risk and roll if calendar volatility compresses.
• Hedge acquirer exposure (12–24 month horizon): Buy DHR put spread or sell covered calls on DHR to hedge potential EPS dilution or integration execution risk. Rationale: acquirer faces execution and goodwill risk; small, inexpensive downside protection preserves upside in broader market rallies while capping large drawdowns from deal disappointments.